PMID- 30546448
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 16
IP  - 6
DP  - 2018 Dec
TI  - Oxidative stress induced by carboplatin promotes apoptosis and inhibits migration 
      of HN-3 cells.
PG  - 7131-7138
LID - 10.3892/ol.2018.9563 [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC) is currently a serious public health 
      problem in China; thus, it is urgent to identify effective treatment strategies 
      for this disease. Previous studies demonstrated that reactive oxygen species 
      (ROS) serve important roles in the apoptosis of LSCC cells. It has also been 
      indicated that carboplatin (CBDCA), a second-generation platinum compound with 
      broad antineoplastic properties, is able to induce oxidative stress to produce 
      ROS, which in turn promotes apoptosis. Thus, the present study investigated if 
      CBDCA is cytotoxic in LSCC cells due to the oxidative stress caused by ROS. 
      Therefore, an MTT assay was performed to determine the cell viability of HN-3 
      LSCC cells following treatment with different doses of CBDCA. Subsequently, the 
      expression levels of ROS and the rate of apoptosis/necrosis were evaluated in the 
      cells. Following this, the HN-3 cells were co-treated with CBDCA and glutathione 
      (GSH) or H(2)O2, followed by an MTT assay, a cell migration assay and western 
      blot analysis. The results demonstrated that CBDCA reduced the viability of HN-3 
      cells in a time- and dose-dependent manner and promoted the production of ROS and 
      apoptosis at certain doses. Additionally, the combination treatment of CBDCA and 
      H2O2 enhanced the inhibitory effects of CBDCA on cell viability and migration 
      ability, and promoted apoptosis in HN-3 cells; whereas the combined treatment of 
      CBDCA and GSH exerted opposite effects. The results of the present study 
      demonstrated that CBDCA promotes the apoptosis of HN-3 cells through accumulation 
      of ROS, which may provide a novel treatment strategy for treating LSCC.
FAU - He, Pei-Jie
AU  - He PJ
AD  - Department of Otolaryngology-Head and Neck Surgery, Shanghai Key Clinical 
      Disciplines of Otorhinolaryngology, Eye and ENT Hospital of Fudan University, 
      Shanghai 200031, P.R. China.
AD  - Department of Otolaryngology, Shanghai Public Health Clinical Center, Fudan 
      University, Shanghai 201508, P.R. China.
FAU - Ge, Rui-Feng
AU  - Ge RF
AD  - Department of Otolaryngology-Head and Neck Surgery, The Affiliated Hospital of 
      Qingdao University, Qingdao, Shandong 266003, P.R. China.
FAU - Mao, Wen-Jing
AU  - Mao WJ
AD  - Department of Otolaryngology-Head and Neck Surgery, Shanghai Key Clinical 
      Disciplines of Otorhinolaryngology, Eye and ENT Hospital of Fudan University, 
      Shanghai 200031, P.R. China.
FAU - Chung, Phil-Sang
AU  - Chung PS
AD  - Department of Otolaryngology-Head and Neck Surgery, Beckman Laser Institute 
      Korea, Dankook University, Cheonan, South Chungcheong 330-715, Republic of Korea.
FAU - Ahn, Jin-Chul
AU  - Ahn JC
AD  - Department of Otolaryngology-Head and Neck Surgery, Beckman Laser Institute 
      Korea, Dankook University, Cheonan, South Chungcheong 330-715, Republic of Korea.
FAU - Wu, Hai-Tao
AU  - Wu HT
AD  - Department of Otolaryngology-Head and Neck Surgery, Shanghai Key Clinical 
      Disciplines of Otorhinolaryngology, Eye and ENT Hospital of Fudan University, 
      Shanghai 200031, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20181010
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC6256460
OTO - NOTNLM
OT  - apoptosis
OT  - carboplatin
OT  - laryngeal squamous cell carcinoma
OT  - oxidative stress
OT  - reactive oxygen species
EDAT- 2018/12/14 06:00
MHDA- 2018/12/14 06:01
PMCR- 2018/10/10
CRDT- 2018/12/15 06:00
PHST- 2017/12/20 00:00 [received]
PHST- 2018/09/07 00:00 [accepted]
PHST- 2018/12/15 06:00 [entrez]
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2018/12/14 06:01 [medline]
PHST- 2018/10/10 00:00 [pmc-release]
AID - OL-0-0-9563 [pii]
AID - 10.3892/ol.2018.9563 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Dec;16(6):7131-7138. doi: 10.3892/ol.2018.9563. Epub 2018 Oct 
      10.